| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jin W et al. | LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. | 2018 | Bioanalysis | pmid:29863890 |
| Menchon G et al. | A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. | 2018 | Nat Commun | pmid:29844393 |
| Johnson TA and Singla DK | Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. | 2018 | Can. J. Physiol. Pharmacol. | pmid:29842793 |
| Barok M et al. | Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. | 2018 | BMC Cancer | pmid:29720111 |
| Sakai H et al. | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. | 2018 | Breast Cancer | pmid:29700710 |
| Escrivá-de-Romanà S et al. | HER2-positive breast cancer: Current and new therapeutic strategies. | 2018 | Breast | pmid:29631097 |
| Moore KN et al. | FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. | 2018 | Future Oncol | pmid:29424243 |
| Ricciardi GRR et al. | Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. | 2018 | BMC Cancer | pmid:29370839 |
| Yeo W et al. | Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. | 2018 | Hong Kong Med J | pmid:29326401 |
| Gligorov J et al. | Emilia: use cunning to survive cancer. | 2018 | Chin Clin Oncol | pmid:29307196 |